Literature DB >> 18369397

Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Yonghua Zhang1, Harold K Kimelberg.   

Abstract

Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2-adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.

Entities:  

Keywords:  Alpha 2-adrenergic agonist; adrenoceptor; cerebral ischemia; excitatory amino acids; imidazoline receptor; neuroprotection; stroke; sympathoinhibition

Year:  2005        PMID: 18369397      PMCID: PMC2268994          DOI: 10.2174/157015905774322534

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  78 in total

1.  Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype.

Authors:  D B Bylund; C Ray-Prenger
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  Presynaptic inhibition of excitatory synaptic transmission mediated by alpha adrenergic receptors in area CA3 of the rat hippocampus in vitro.

Authors:  M Scanziani; B H Gähwiler; S M Thompson
Journal:  J Neurosci       Date:  1993-12       Impact factor: 6.167

Review 3.  Catecholamine receptors and signal transduction. Overview.

Authors:  D S Goldstein
Journal:  Adv Pharmacol       Date:  1998

Review 4.  Presynaptic alpha-autoreceptors.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1987       Impact factor: 5.545

5.  Ultrastructural features of a brain injury model in cat. I. Vascular and neuroglial changes and the prevention of astroglial swelling by a fluorenyl (aryloxy) alkanoic acid derivative (L-644,711).

Authors:  K D Barron; M P Dentinger; H K Kimelberg; L R Nelson; R S Bourke; S Keegan; R Mankes; E J Cragoe
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  Monoamine neurotransmitters in the evolution of infarction in ischemic striatum: morphologic correlation.

Authors:  J Weinberger; J Nieves-Rosa
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 7.  Adrenoceptors and their second messenger systems.

Authors:  R J Summers; L R McMartin
Journal:  J Neurochem       Date:  1993-01       Impact factor: 5.372

8.  Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling.

Authors:  P P Lakhlani; D M Lovinger; L E Limbird
Journal:  Mol Pharmacol       Date:  1996-07       Impact factor: 4.436

9.  Clonidine preconditioning decreases infarct size and improves neurological outcome from transient forebrain ischemia in the rat.

Authors:  Y Zhang
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 10.  Clinical experience with excitatory amino acid antagonist drugs.

Authors:  K W Muir; K R Lees
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

View more
  11 in total

1.  Effects of precondition α2-adrenoceptor agents on memory- and anxiety-related processes in the transient cerebral ischemic rats.

Authors:  Mohammad Nasehi; Esmail Imani; Mohaddeseh Ebrahimi-Ghiri; Vahid Sabouri-Khanghah; Mohammad-Reza Zarrindast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-15       Impact factor: 3.000

2.  Guanabenz mitigates the neuropathological alterations and cell death in Alzheimer's disease.

Authors:  Abhishek Singh; Parul Gupta; Shubhangini Tiwari; Amit Mishra; Sarika Singh
Journal:  Cell Tissue Res       Date:  2022-02-23       Impact factor: 5.249

3.  Dexmedetomidine inhibits tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide-stimulated astrocytes by suppression of c-Jun N-terminal kinases.

Authors:  Xiaobao Zhang; Jun Wang; Wenyi Qian; Jingjing Zhao; Li Sun; Yanning Qian; Hang Xiao
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-adrenergic receptor signaling after rat spinal cord injury.

Authors:  Jiandong Gao; Zhihua Sun; Zhaoyang Xiao; Qihang Du; Xinhuan Niu; Gongming Wang; Yu-Wen Chang; Yongtao Sun; Wei Sun; Amity Lin; Jacqueline C Bresnahan; Mervyn Maze; Michael S Beattie; Jonathan Z Pan
Journal:  Br J Anaesth       Date:  2019-10-14       Impact factor: 9.166

5.  Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study.

Authors:  Paulo Gabriel Melo Brandão; Francisco Ricardo Lobo; Serginando Laudenir Ramin; Yasser Sakr; Mauricio Nassau Machado; Suzana Margareth Lobo
Journal:  Braz J Cardiovasc Surg       Date:  2016 May-Jun

6.  Dexmedetomidine alleviates cerebral ischemia-induced short-term memory impairment by inhibiting the expression of apoptosis-related molecules in the hippocampus of gerbils.

Authors:  In-Young Choi; Lakkyong Hwang; Jun-Jang Jin; Il-Gyu Ko; Sung-Eun Kim; Mal-Soon Shin; Key-Moon Shin; Chang-Ju Kim; Sung-Wook Park; Jin-Hee Han; Jae-Woo Yi
Journal:  Exp Ther Med       Date:  2016-12-05       Impact factor: 2.447

7.  Low Dose Dexmedetomidine Attenuates Hemodynamic Response to Skull Pin Holder Application.

Authors:  Shwethashri Ramaprasannakumar Kondavagilu; Vinayak Seenappa Pujari; Mohan V R Chadalawada; Yatish Bevinguddaiah
Journal:  Anesth Essays Res       Date:  2017 Jan-Mar

Review 8.  Critical Evaluation of the Lund Concept for Treatment of Severe Traumatic Head Injury, 25 Years after Its Introduction.

Authors:  Per-Olof Grände
Journal:  Front Neurol       Date:  2017-07-04       Impact factor: 4.003

9.  Antioxidant effects of dexmedetomidine against hydrogen peroxide-induced DNA damage in vitro by alkaline Comet assay

Authors:  Mustafa Sirri Kotanoğlu; Ela Kadioğlu; Esra Emerce; Çetin Kaymak; Ayşe Özcan; Hülya Başar
Journal:  Turk J Med Sci       Date:  2020-08-26       Impact factor: 0.973

Review 10.  The Current Role of Dexmedetomidine as Neuroprotective Agent: An Updated Review.

Authors:  Zaara Liaquat; Xiaoying Xu; Prince Last Mudenda Zilundu; Rao Fu; Lihua Zhou
Journal:  Brain Sci       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.